| Literature DB >> 19914780 |
Maria Abbondanza Pantaleo1, Margherita Nannini, Monica Di Battista, Fausto Catena, Guido Biasco.
Abstract
Resistance to tyrosine-kinase inhibitors remains an open issue in the treatment of patients with gastrointestinal stromal tumors. The complex biology of disease in the multi-resistant setting has led a progressively growing urgency and interest in development combined or integrated therapies. This mini-review outlines the rationale for developing new combined therapeutic approaches, and describes the state of the art of the various potential strategies and the promising research perspectives. 2009 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19914780 DOI： 10.1016/j.ctrv.2009.10.004
Source DB: PubMed Journal: Cancer Treat Rev ISSN： 0305-7372 Impact factor: 12.111